Ascendis Pharma Q2 FY26 swings to net profit of €207 million; revenue more than doubles to €339 million

• Ascendis Pharma posted Q2 2026 revenue of EUR 339 million, more than doubled year over year, with product revenue up 105% to EUR 315 million.
• IFRS net profit swung to EUR 207 million, or EUR 2.83 per diluted share, from a loss a year earlier.
• IFRS operating profit turned to EUR 220 million, helped by EUR 158 million of other operating income from a PRV sale.
• YORVIPATH revenue climbed to EUR 252 million, while SKYTROFA generated EUR 55 million; YUVIWEL contributed EUR 8 million.
• Management cited strong demand for TransCon products; YUVIWEL topped 220 U.S. patient enrollments through July 31.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608130730PRIMZONEFULLFEED9809465) on August 13, 2026, and is solely responsible for the information contained therein.